2024-10-05 - Analysis Report
## Amgen Inc. (AMGN) Stock Analysis

**Company Overview:** Amgen Inc. is a leading biotechnology company that develops, manufactures, and markets innovative medicines for serious illnesses.

**Performance Analysis:**

1. **Relative Performance:**
    - AMGN's cumulative return is 78.8%, lagging behind the S&P 500 (VOO) cumulative return of 131.45%.
    - The current divergence is -52.65%, meaning AMGN has underperformed the S&P 500 by that margin.
    - The relative divergence score of 33.34% indicates that the current underperformance is in the lower 33% percentile of historical divergence values. 

2. **Recent Price Movement:**
    - Closing price: $319.73
    - 5-day moving average: $321.81
    - 20-day moving average: $327.83
    - 60-day moving average: $328.54

3. **Technical Indicators:**
    - RSI: 41.55 - Suggests that the stock is in a neutral territory, neither overbought nor oversold.
    - PPO: -0.46 - Indicates a bearish trend, as the PPO is negative.
    - Delta_Previous_Relative_Divergence: -12.9 - Shows a recent decrease in relative divergence, suggesting a potential for the stock to catch up to the S&P 500.
    - Expected_Return: 0.0% - This indicates a zero-percent potential excess return over the next five years compared to the S&P 500, considering the current investment amount.

4. **Recent Earnings & Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-07 | 1.39 | 8.39 B$ |
| 2024-05-03 | -0.21 | 7.45 B$ |
| 2023-10-31 | 3.23 | 6.90 B$ |
| 2023-08-04 | 2.58 | 6.99 B$ |
| 2024-08-07 | 2.58 | 6.99 B$ |

The latest earnings report on August 7th, 2024, showed an EPS of $1.39, exceeding analyst expectations. Revenue also surpassed estimates, reaching $8.39 billion. This strong performance suggests continued momentum in Amgen's business.

5. **News & Recent Issues:**

- **Recent Market Outlook:** Amgen's stock has been facing downward pressure due to its underperformance relative to the broader market. However, the company's strong recent earnings results and a robust pipeline of innovative therapies could drive future growth.
- **Analyst Opinions:**  Analysts are generally bullish on AMGN, with a consensus "Buy" rating. They highlight Amgen's leading position in the biopharmaceutical sector, its diversified product portfolio, and its potential for future growth. 
- **Performance Highlights:** Amgen's innovative drug development and strong market position have resulted in significant revenue growth and profitability in recent years. However, the company faces competition in several of its core markets, which poses a challenge to continued growth.

**Summary:**

Amgen Inc. (AMGN) is a leading biotechnology company with a strong track record of innovation and profitability. Although its recent performance has lagged behind the S&P 500, its latest earnings report and a robust pipeline of innovative therapies suggest potential for future growth. Analysts are generally bullish on the stock, citing its leading market position, diversified product portfolio, and potential for future growth. However, investors should monitor competition in its core markets and the company's ability to maintain its growth trajectory. Overall, AMGN remains a valuable addition to any diversified portfolio. 
